M&A Deal Summary |
|
|---|---|
| Date | 2024-02-25 |
| Target | iBio - Preclinical PD-1 Agonist Antibody Program |
| Sector | Life Science |
| Buyer(s) | Otsuka |
| Sellers(s) | iBio |
| Deal Type | Divestiture |
| Deal Value | 53M USD |
SEARCH BY
| Category | Company |
|---|---|
| Founded | 1921 |
| Sector | Healthcare Services |
| Employees | 35,338 |
| Revenue | 2.33T JPY (2024) |
Otsuka engages in pharmaceuticals, nutraceuticals, consumer products, and other businesses worldwide. Otsuka was founded in 1921 and is based in Tokyo, Japan.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 9 |
| Sector: Life Science M&A | 4 of 5 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 6 of 7 |
| Year: 2024 M&A | 1 of 2 |
| Size (of disclosed) | 7 of 7 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2018-07-11 |
Visterra
Waltham, Massachusetts, United States Visterra, Inc. is a clinical stage biotechnology company committed to developing innovative antibody-based therapies for the treatment of patients with kidney diseases and other hard-to-treat diseases. Visterra is based in Waltham, Massachusetts. |
Buy | $430M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2024-08-01 |
Jnana Therapeutics
Boston, Massachusetts, United States Jnana Therapeutics is developing drugs against a broad family of metabolite transport proteins to treat high unmet needs in auto-immune, immuno-metabolism, and other diseases. Jnana Therapeutics was founded in 2017 and is based in Boston, Massachuserrs. |
Buy | $800M |
| Category | Company |
|---|---|
| Founded | 2008 |
| Sector | Life Science |
| Employees | 16 |
| Revenue | 2M USD (2022) |
iBio develops next-generation biopharmaceuticals using computational biology and 3D-modeling of hard-to-target subdominant epitopes along with its sustainable, plant-based protein expression capabilities for cGMP manufacturing. iBio was founded in 2008 and is based in San Diego, California.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 1 |
| Sector: Life Science M&A | 1 of 1 |
| Type: Divestiture M&A Deals | 1 of 1 |
| State: Texas M&A | 1 of 1 |
| Country: United States M&A | 1 of 1 |
| Year: 2024 M&A | 1 of 1 |
| Size (of disclosed) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2022-09-21 |
RubrYc
San Carlos, California, United States RubrYc is a biotechnology company that integrates chemistry and computation to discover and develop antibody-based drugs with unprecedented epitope selectivity. RubrYc was founded in 2017 and is based in San Carlos, California. |
Buy | - |
